BUSINESS
Edgewise Cashed Out Before Sevasemten Failed Its Pivotal Trial
Edgewise already collected $1.55 billion in cash for sevasemten; Servier’s 18-month GRAND CANYON trial in Becker muscular dystrophy missed every efficacy goal.
Servier said November 3 that sevasemten missed its main function test in an 18-month Becker muscular dystrophy trial. The French group had paid Edgewise Therapeutics $1.55 billion in cash for the drug on July 10, plus up to $1.1 billion more if later goals were hit.
Edgewise already has that cash and is now a heart-drug company. Servier holds a missed registration study. People with Becker still have no approved treatment aimed at the disease itself.
Edgewise Already Banked the $1.55 Billion
On June 1, Servier said it would acquire the muscular dystrophy business of Edgewise, including sevasemten (also called EDG-5506), related patents, trial data, filings, and a core staff group that was offered jobs at Servier. The asset purchase agreement was dated May 31. The deal closed July 10, and Edgewise confirmed the close on July 13.
Edgewise’s filing said the buyer paid $1.55 billion in upfront cash and left up to $1.1 billion in regulatory and commercial milestones on the table, for a package of up to $2.65 billion. The Boulder company said those proceeds, on top of cash it already held, should fund EDG-7500, its hypertrophic cardiomyopathy candidate, through a possible approval, and support EDG-15400 in heart failure with preserved ejection fraction.
Kevin Koch, Edgewise’s president and chief executive, called the close a milestone for the company and for sevasemten and said Servier’s scale would help “fully realize sevasemten’s potential for individuals living with Becker and Duchenne muscular dystrophy.” That was 116 days before Servier posted the miss.
FROM THE JUNE SALE TO THE MISS
- March 10, 2026: Edgewise presents MESA open-label data at the MDA conference, saying North Star scores stayed stable for up to 3.5 years.
- June 1, 2026: Servier announces the purchase of Edgewise’s muscular dystrophy unit for up to $2.65 billion.
- July 10, 2026: The sale closes and $1.55 billion in cash moves to Edgewise.
- November 3, 2026: Servier says the 18-month GRAND CANYON study missed its primary North Star endpoint and missed secondary endpoints.
Some muscle-disease watchers had been saying since late 2024 that a long placebo-controlled North Star readout would not copy those open-label charts. The sale still closed in the last clean window before that binary test, which is why Edgewise’s listed shares were not set up for a classic Phase 3 wipeout.
No Benefit on the 18-Month Walk Test
Sevasemten is an oral fast skeletal myosin inhibitor, taken once a day at night at a 10 mg adult dose, meant to ease the force of contraction so fragile muscle is damaged less when dystrophin is missing or weak. GRAND CANYON was the 175-adult pivotal cohort added onto the earlier CANYON study. It ran 18 months against placebo, with change on the North Star Ambulatory Assessment, a scored set of everyday movement tasks, as the main measure.
Servier said topline results showed no statistically significant benefit on that scale. Secondary endpoints were not met either. The company said a favorable safety and tolerability profile was maintained, and that full results will be presented later.
GRAND CANYON TOPLINE
- Cohort size: 175 adults with Becker muscular dystrophy, in a global placebo-controlled study.
- Duration: 18 months on sevasemten or placebo, with North Star change as the main test.
- Efficacy: Primary North Star goal missed; secondary goals missed as well.
- Safety: Servier said the safety and tolerability profile stayed favorable.
Before the sale, Edgewise had told investors the cohort was fully enrolled and powered at greater than 98% to find a difference versus placebo, with topline data due in the fourth quarter of 2026. The calendar hit that window. The function test did not.
Servier’s own line was careful. “The results of the pivotal GRAND CANYON study are not aligned with certain findings observed in prior clinical studies, including the Phase 2 CANYON study,” the company said. It is running a full review of the new dataset next to those earlier results.
Why the Smaller Studies Looked Cleaner
The pitch that supported a $1.55 billion check was not a completed registration win. It was a biomarker result in a smaller blinded study, plus open-label North Star scores that stayed flat while natural-history papers predicted a slide.
CANYON tested sevasemten for a year in 40 men and 29 adolescent boys. In adults the dose was 10 mg; adolescents received 5 mg or 12.5 mg. The study met its main goal with a 28% drop in creatine kinase, a blood marker of muscle leak, versus placebo (p=0.02). Fast skeletal troponin I, another damage marker, fell 77% versus placebo (p<0.001). North Star scores in treated adults were described as stable, with a trend toward improvement, while the placebo group declined.
That function read was never clean. At baseline, treated adults already sat at a mean North Star of 18.4 points (n=28) against 24.2 on placebo (n=12), a 5.8-point gap (p=0.04). Edgewise’s own CANYON slides said the imbalance “confounded interpretation” of some endpoints. The blinded year did not deliver a statistically clear North Star win. The later 18-month study asked that question at scale and did not get a yes.
TWO DATASETS, TWO STORIES
| Item | CANYON and MESA | GRAND CANYON |
|---|---|---|
| Who was studied | 40 men and 29 adolescents (CANYON); MESA rolled over prior cohorts | 175 adults in the pivotal cohort |
| How long | 1 year blinded; open-label follow-up to 2 and 3.5 years | 18 months, placebo-controlled |
| Main number reported | 28% CK drop vs placebo; North Star +0.1 vs predicted decline | North Star primary missed; secondaries missed |
| How function was judged | Trends in a small blinded arm, then open-label vs natural history | Direct 18-month test against placebo |
| Safety | Favorable; common later events included falls and joint pain | Favorable, per Servier |
MESA, the open-label extension, is the dataset that made the function story feel durable. Edgewise said 99% of eligible people from ARCH, CANYON, GRAND CANYON, and DUNE chose to enroll. After two years, CANYON participants on drug had gained 0.1 North Star points against a predicted 2.9-point decline. After 3.5 years, the smaller ARCH group had gained 0.1 points against a predicted 5.3-point decline. Natural-history papers cited by the company put typical yearly North Star loss at 1.0 to 1.7 points once decline has started.
Joanne Donovan, then Edgewise’s chief medical officer, used that contrast in March, months before the cash moved.
For the first time with an investigational agent, we are seeing long-term data where individuals with Becker are stable in the face of a disease that we have seen would otherwise lead to a significant functional decline.
Joanne Donovan, Chief Medical Officer, Edgewise Therapeutics, MDA Conference, March 2026
Edgewise also reported stabilization of function over 3.5 years in that MESA update and said it remained on track for a first marketing application if GRAND CANYON was positive. Placebo-controlled walking scores over 18 months did not follow the open-label line. That is the gap Servier now has to explain in the full tables.
The 12,000 People With Nothing Approved
Becker muscular dystrophy is a rare, X-linked condition that mostly affects males. Mutations in the dystrophin gene leave muscle open to contraction injury, with progressive loss of motor function and a shorter life. Edgewise put the diagnosed population at about 12,000 people in the United States, the EU-5, and Japan. No approved therapy treats the underlying disease.
Sevasemten had collected FDA Orphan Drug status for Becker and Duchenne, Fast Track for both, a Rare Pediatric Disease designation for Duchenne, and EMA Orphan status for both. Those badges do not replace a function win. They also do not create a backup drug. Other Becker programs remain earlier in development, including work on givinostat, vamorolone, and several preclinical or early clinical candidates, none of which stood in for an 18-month registration test.
The Muscular Dystrophy Association, in a November 3 note from Chicago, said the 18-month global trial did not demonstrate efficacy in adults with Becker and missed secondary endpoints. CureDuchenne called the same topline disappointing and said it would pass along more detail as Servier releases it.
“While we are disappointed that this trial did not demonstrate efficacy in adults with BMD, clinical research advances our understanding of the disease and informs the path forward,” the association said. It argued GRAND CANYON still moved outcome measures and trial design for the next attempt. MDA also said it plans an educational webinar with Servier staff so families can ask about the data, with registration details still to come.
For the people who spent 18 months in a placebo-controlled study, and for the 99% who had rolled into open-label MESA on the promise of stable scores, the topline is a hard stop. Care today is still supportive: physical therapy, cardiac watch, and the same absence of a disease-modifying label that existed before CANYON.
The Buyer Now Owns a Missed Pivotal Study
Servier is an independent international group governed by a foundation, based in Suresnes, France. There is no public share price that has to reprice this miss overnight. That is the other half of the split: Edgewise, the listed seller, booked the cash in July; Servier, the unlisted buyer, owns the trial that just missed.
Olivier Laureau, Servier’s president, had tied the close to the company’s 2030 plan to become a player in rare neurology. He welcomed the Edgewise muscle team and called Becker and Duchenne a strategic step toward serving people with “devastating rare diseases.”
This is a strategic milestone in achieving Servier 2030 to become a new player in rare neurology and to serve patients living with devastating rare diseases.
Olivier Laureau, President, Servier, July 13, 2026 closing statement
In its June 1 statement, Servier called sevasemten a late-stage, first-in-class oral myosin inhibitor and said the purchase supported its rare-neurology ambition for patients with high unmet need. The 18-month study was the first large test of that claim under Servier’s name. The company now says it is doing a comprehensive analysis of GRAND CANYON next to prior clinical data “to better understand and further characterize the study findings.”
The remaining $1.1 billion is written as regulatory and commercial milestones. A Becker approval in the United States was the nearest of those events on the old calendar. That path is now in doubt until Servier shows a subgroup, a biomarker, or some other reading that the North Star primary did not. A foundation-owned buyer can sit with a missed study longer than a listed one. It still paid cash for a trial Edgewise had described as more than 98% powered to succeed.
What Servier Still Holds in Duchenne
The purchase was the whole muscular dystrophy unit, not a Becker-only license. Sevasemten is still in Phase 2 for Duchenne muscular dystrophy, a more severe dystrophinopathy that already has approved drugs, including gene therapy. Servier has not said whether those studies change after the Becker miss.
PROGRAMS SERVIER STILL RUNS
- LYNX: A Phase 2 trial in 76 boys with Duchenne that helped pick the 10 mg dose and is in open-label follow-up.
- FOX: A Phase 2 trial in 43 children and adolescents with Duchenne who already received gene therapy, also past its short placebo window.
- MESA: The Becker open-label extension that had taken in 99% of eligible prior participants.
- GRAND CANYON dataset: Full tables, including biomarkers and any subgroup cuts, still unreleased.
In June 2025, Edgewise had said LYNX showed encouraging trends on stride velocity and other function measures and that FOX’s early data also supported 10 mg. Those were short, dose-finding looks, not an 18-month North Star test. A Duchenne Phase 3 design had been slated for the second half of 2026 if the Becker pivotal data were positive. That plan now sits with Servier, which has not given a new date.
WHAT WE KNOW
- The miss: GRAND CANYON did not beat placebo on North Star and did not meet secondary endpoints.
- The cash: Edgewise received $1.55 billion on July 10 and is running a cardiovascular pipeline.
- The gap: Becker still has no approved disease-modifying therapy.
WHAT IS UNCONFIRMED
- Any filing: Servier has not said whether it will take Becker data to regulators.
- Duchenne Phase 3: No new start date has been given since the Becker miss.
- Hidden cuts: Biomarker and subgroup results from the 18-month study have not been shown.
Until those tables appear, the split on this drug is already set. Edgewise used sevasemten to fund a heart franchise. Servier owns an oral myosin inhibitor that did not slow Becker on the scale it picked, and about 12,000 patients are in the same place they were before the $1.55 billion changed hands. MDA’s promised webinar is the next date on the calendar that families can actually use.
Disclaimer: This article is news reporting and analysis of a clinical-trial readout and a completed asset sale. It is for information only and is not medical advice, investment advice, or a recommendation to start, stop, or change any treatment or to buy or sell any security. Readers who have Becker or Duchenne muscular dystrophy, or who care for someone who does, should talk with a neuromuscular specialist before making any care decision, and readers looking at Edgewise or related securities should consult a licensed financial adviser. Figures, trial statuses, and milestone terms reflect the company statements and filings cited here as of November 3, 2026, and may change when Servier releases the full GRAND CANYON dataset.
-
NEWS2 months agoAI Server Boards Put Everyday Circuit Materials on Allocation
-
NEWS3 months agoGlacier Collapse Buried Nepal’s Hydropower Workers in Tunnels
-
NEWS3 months agoCongo’s Bundibugyo Outbreak Outruns the Licensed Ebola Shots
-
NEWS3 months agoPennsylvania Measles Deaths Follow a Long Slide in Coverage
-
NEWS3 months agoCISA’s Known Exploits Still Come From 2007-Era Bugs
-
NEWS3 months agoTexas Judge Freezes the SEC Eligibility Ban for 41 Athletes
-
NEWS3 months agoGermany Can Miss Its 2026 Climate Cap Without Penalty
-
NEWS3 months agoFDA Approves XFG COVID-19 Vaccines Without a CDC Vote
